EP2533683A1 - Method of characterizing the pathological response of tissue to a treatmant plan - Google Patents

Method of characterizing the pathological response of tissue to a treatmant plan

Info

Publication number
EP2533683A1
EP2533683A1 EP11742965A EP11742965A EP2533683A1 EP 2533683 A1 EP2533683 A1 EP 2533683A1 EP 11742965 A EP11742965 A EP 11742965A EP 11742965 A EP11742965 A EP 11742965A EP 2533683 A1 EP2533683 A1 EP 2533683A1
Authority
EP
European Patent Office
Prior art keywords
tissue
biomechanical property
trend
tumor
volume average
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11742965A
Other languages
German (de)
French (fr)
Other versions
EP2533683A4 (en
Inventor
Nebojsa Duric
Peter John Littrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delphinus Medical Technologies Inc
Original Assignee
Delphinus Medical Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delphinus Medical Technologies Inc filed Critical Delphinus Medical Technologies Inc
Priority claimed from PCT/US2011/024765 external-priority patent/WO2011100691A1/en
Publication of EP2533683A1 publication Critical patent/EP2533683A1/en
Publication of EP2533683A4 publication Critical patent/EP2533683A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/43Detecting, measuring or recording for evaluating the reproductive systems
    • A61B5/4306Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
    • A61B5/4312Breast evaluation or disorder diagnosis

Definitions

  • This invention relates generally to the medical field, and more specifically to an improved method of characterizing the pathological response of tissue to a treatment plan in the cancer treatment field.
  • Common treatments for cancer include removal of cancerous tumor tissue from the patient, radiation treatment, chemotherapy, or ablation interventions, but the most effective treatment or combinations of treatments typically varies from patient to patient. For example, not all cancer patients respond to certain treatments like chemotherapy and radiation treatment, and furthermore not all responsive cancer patients have equal success with these treatments.
  • the success of a treatment for a patient is often not known until the end of the treatment or after a follow-up period after the treatment. However, it is advantageous to be able to accurately predict whether a patient will respond well to a treatment, particularly earlier in the treatment plan, to guide implementation of alternative regimens and/or to abort an unsuccessful treatment plan.
  • FIGURE l is a schematic of the method of a preferred embodiment
  • FIGURE 2 is a schematic of a scanner that may be used during the step of obtaining a set of sequential morphological renderings of tissue in the method of a preferred embodiment
  • FIGURES 3A-3D are schematics of steps of obtaining a set of sequential morphological renderings of tissue in the method of a preferred embodiment;
  • FIGURE 4 is a schematic of the step of generating a set of representative values in the method of a preferred embodiment;
  • FIGURES 5 and 6 are schematics of variations of determining a trend of the biomechanical property based on a set of representative values of a biomechanical property in the method of a preferred embodiment.
  • FIGURE 7 is a schematic of one variation of predicting response of tissue to a treatment plan based on the trend of a biomechanical property in the method of a preferred embodiment.
  • the method 100 of characterizing the pathological response of tissue to a treatment plan of a preferred embodiment includes the steps of: obtaining a set of sequential morphology renderings of the tissue S110, wherein each rendering corresponds to a particular point in time during the treatment plan; generating a set of representative values of a biomechanical property of the tissue for the set of renderings S120, wherein each representative value is based on a corresponding rendering; determining a trend of the biomechanical property S130 based on the set of representative values; and predicting response of the tissue to the treatment plan S140 based on the trend of the biomechanical property.
  • the method 100 is preferably used to predict and/or monitor the pathological response of cancer, such as breast cancer, to chemotherapy or radiation therapy (or side effects of the therapy), but may additionally and/or alternatively be used to predict or monitor the response of any cancer or benign tumors to any suitable treatment.
  • the method 100 may additionally and/or alternatively be used to predict success of chemoprevention (a pharmacological approach to reducing cancer risk). Predicting and characterizing how a cancer patient will respond to a particular cancer treatment allows a physician to distinguish patients who are likely to have success with the treatment from those patients who are less likely to have success with the treatment, thereby allowing the physician to guide implementation of alternative regimens and/or to abort the particular treatment.
  • Such knowledge about patient response to the treatment enables the physician to, for example, spare an unresponsive patient from suffering side effects of chemotherapy or radiation therapy and from applying potentially limited financial means towards an ineffective treatment, and move towards optimizing the efficacy of a treatment plan.
  • the trend, such as rate of change, of the biomechanical property of the tumor early in the treatment plan is preferably used to predict the full treatment response, but the trend of the biomechanical property at any stage in the treatment plan may additionally and/or alternatively be used.
  • the method 100 may facilitate an accurate and frequent evaluation of the tumor response to other therapies, such as to evaluate the clinical efficacy of a new therapeutic agent or regimen.
  • the step of obtaining a set of sequential morphology renderings Sno functions to obtain data from the patient. This data forms the basis of analysis in characterizing the response of the tissue to a cancer treatment.
  • the morphology renderings preferably include renderings of tumor tissue, and may additionally and/or alternatively include renderings of healthy tissue such as that surrounding the tumor tissue.
  • the morphology renderings may additionally and/or alternatively broken bones or any suitable tissue.
  • Each rendering preferably corresponds to a particular point in time during the treatment plan, such that the set of renderings represent sequential, chronological snapshots of the tissue at various points in time during the treatment plan.
  • obtaining a rendering may be performed hourly, daily, every few days, every 1-3 weeks, or any suitable frequency, or performed in correspondence (e.g., immediately before and/or immediately after) a treatment phase such as a chemotherapy treatment.
  • Obtaining a set of renderings S110 is preferably performed in early stages of a treatment plan (e.g., within the first several months), but may alternatively be performed during any suitable portion of the treatment plan.
  • the set of renderings may be taken at approximately regular time intervals during the treatment plan, or at irregular time intervals (for example, the timing of the renderings may depend on particular scheduling of chemotherapy treatments).
  • obtaining a set of renderings S110 preferably includes scanning the tissue with an ultrasound scanner to obtain acoustic data S112 and creating images representing acoustic parameters of the tissue with the acoustic data S114.
  • the steps of scanning the tissue and creating images are each preferably performed at least once each time a single rendering is obtained, such that the steps of scanning the tissue and creating images are repeated multiple times.
  • Obtaining a set of renderings S110 may additionally and/or alternatively include retrieving a set of images or renderings from a storage device such as a hard drive or an online server, or any suitable storage such as hard copy patient records.
  • the step of scanning the tissue S112 preferably includes surrounding the tissue with a transducer that transmits and receives acoustic waves through the tissue.
  • a transducer that transmits and receives acoustic waves through the tissue.
  • FIGURES 2 and 3A to scan breast tissue of a breast cancer patient with an ultrasound tomography scanner having a ring-shaped transducer, the patient positions themselves face down on a flexible bed having a hole in the chest region of the bed. The breast of the patient passes through the hole in the bed and is positioned within the transducer immersed in a water bath.
  • the ring transducer is preferably fixed to a gantry, and, during the scanning step S112, moves in a vertical path to pass between the chest wall and the nipple region in an anterior-posterior direction, thereby preferably imaging the entire breast (alternatively a selected portion of the breast).
  • the scanner is preferably similar to that described in U.S. Patent Publication No. 2008/0275344 entitled "Method and apparatus for categorizing breast density and assessing cancer risk utilizing acoustic parameters", which is incorporated in its entirety by this reference.
  • the ring transducer may be used to scan any suitable tissue, such as an arm, hand, leg, or foot.
  • the scanner is preferably relatively inexpensive, quick, and more comfortable for the patient and easy to install and operate.
  • the scanning step preferably gathers acoustic data including acoustic reflection from tissue, acoustic attenuation within tissue, and/or acoustic speed within tissue.
  • the scanning step may additionally and/or alternatively gather any other acoustic data or suitable biomechanical property of the tissue.
  • the method may alternatively include obtaining a set of morphology renderings using magnetic resonance imaging (MRI), positron emission tomography (PET), or any suitable device to generate renderings of tissue.
  • MRI magnetic resonance imaging
  • PET positron emission tomography
  • PET may be used to assess metabolic changes in tissue to generate tissue images.
  • the step of creating images representing acoustic parameters of the tissue S114 preferably includes generating one or more two-dimensional (2D) images from the acoustic data obtained during the scanning step, and may include generating one or more three-dimensional (3D) images of the tissue.
  • generating one or more 2D images includes generating a plurality of 2D cross-sectional images (e.g., "slices" in the coronal plane, or any suitable plane) of the tissue S116 and combining the 2D cross-sectional images of the tissue into a 3D image of the tissue S118.
  • the images are preferably tomography images, and more preferably ultrasound tomography images, although they may alternatively be any suitable tomography imges.
  • a general process for combining stacks of 2D images into a 3D image is known by one skilled in the art, but one possible process is described in U.S. Patent Publication No. 2008/0275344.
  • the 2D and/or 3D images may be generated in any suitable manner.
  • the steps of scanning and creating images are preferably repeated until a chronological set of renderings of the tissue (preferably 3D) are obtained, such that the set includes a morphological rendering at times ti, t2, t3... tn are obtained.
  • the images preferably represent at least one of acoustic reflection from the tissue, acoustic attenuation within the tissue, and acoustic speed within the tissue.
  • the images may additionally and/or alternatively represent any suitable biomechanical property of the tissue.
  • the images may represent the tissue under Doppler radar or the interaction of the tissue with a contrast agent (e.g., uptake or kinetics of flow).
  • each acoustic parameter is preferably imaged in a separate stack of 2D images, such that at each cross-sectional level in the stack, the images for acoustic reflection (Ir), attenuation (la), and/or acoustic speed (Is) can be overlaid or combined into a merged 2D image.
  • Ir acoustic reflection
  • la attenuation
  • Is acoustic speed
  • the step of generating a set of representative values of a biomechanical property S120 functions to quantify or otherwise characterize the biomechanical property in the set of renderings.
  • the step of generating a set of representative values S120 preferably includes calculating an average value of the biomechanical property for each rendering S122, thereby generating a set of sequential or chronological volume average values of the biomechanical property of the tissue.
  • Generating a set of representative values S120 may further include normalizing the set of representative values, such as to remove statistical error from the measured data.
  • the generated representative values of the set of renderings are preferably of acoustic speed, but may additionally and/or include acoustic attenuation, acoustic speed, tissue density, and/or any suitable biomechanical property.
  • the average value is a volume average of the biomechanical property in a primary tumor in the patient.
  • the primary tumor is preferably defined by locating an outline of the tumor mass as it appears on the morphology renderings of the acoustic reflection image, and the tumor outline may be replicated on the acoustic attenuation and/or acoustic speed morphology renderings to show the boundary of the primary tumor.
  • the volume average preferably incorporates the mean value of the biomechanical property within the volume of the primary tumor as characterized by the renderings. For example, an average volumetric acoustic speed may be calculated as described in U.S. Patent Publication No. 2008/0275344.
  • the volume average may be a representative value of the biomechanical property in the primary tumor calculated in any suitable manner.
  • the volume average may additionally and/or alternatively include other aspects, such as being weighted by a spatial distribution of the values of the biomechanical property throughout the primary tumor.
  • the volume average may take into account a combination of multiple different kinds of biomechanical properties throughout the primary tumor.
  • the average value may be the mean or other statistical average of multiple volume averages of the multiple tumors, or the maximum volume average value of the multiple volume averages of multiple tumors. In another variation, the average value is the mean or other statistical average of any suitable healthy or unhealthy portion of the rendered tissue. However, the average value may alternatively be any suitable average value.
  • Calculating an average value of the biomechanical property for each rendering S122 preferably includes accounting for the difference between the value of the biomechanical property within the tumor tissue and the value of the biomechanical property in background tissue surrounding the tumor tissue S124. Accounting for the difference functions to disregard the value of the biomechanical property in the background tissue. Preferably, accounting for the difference S124 includes subtracting an average value of the biomechanical property in background tissue from the volume average value of the biomechanical property of the tumor tissue S126, but the difference may be accounted for in any suitable manner.
  • the boundary of background tissue relative to tumor tissue in each rendering may be defined in one or more of several manners.
  • the background tissue may be defined as a region beyond a distance threshold (e.g., 2 centimeters) beyond the boundary of the outlined tumor tissue.
  • the background tissue may be defined as a region beyond a boundary where the gradient in the biomechanical property satisfies a difference threshold.
  • the boundary of background tissue relative to tumor tissue may be defined in any suitable manner.
  • generating a set of representative values S120 includes determining an initial or baseline value of the biomechanical property, or any suitable singular value of the biomechanical property.
  • the initial value may be taken from the first rendering obtained in step S110.
  • determining a trend of the biomechanical property S130 may include characterizing initial values of multiple biomechanical properties, or any suitable singular values of multiple biomechanical properties.
  • generating a set of representative values S120 may include characterizing the spatial distribution of the biomechanical property in each of the set of renderings.
  • the characterization may be qualitative, or may be quantitative such as by generating a parameter descriptive of the spatial distribution of the biomechanical property.
  • Generating a set of representative values S120 may include characterizing the spatial distribution of acoustic speed in an acoustic rendering, but may additionally and/or alternatively include characterizing the spatial distribution of acoustic attenuation or any suitable biomechanical property.
  • the step of determining a trend of the biomechanical property S130 functions to generate metrics, based on the acoustic data, that may be analyzed for predicting or otherwise characterizing patient response to a treatment plan.
  • Determining a trend S130 preferably includes calculating a rate of change in the set of average values S132, which may be one or more of several variations.
  • determining a trend of the biomechanical property S130 includes graphing the set of average values of the biomechanical property on a plot against a temporal variable (e.g., number of days of treatment or number of treatments) S134.
  • Each value of the set of average values may be expressed as an absolute value, expressed as a percentage of the first average value of the set, or in any suitable manner.
  • calculating a rate of change S132 preferably includes calculating a slope of a best-fit curve fitted to at least a portion of the plot.
  • the calculated rate of change in the biomechanical property may be the slope of a best-fit curve fitted to two or more values in the set of volume average values.
  • the calculated rate of change may be the slope between the first and last average values, the mean or median of slopes between subsets of adjacent pairs of average values, percentage difference between two or more points on the plots, or any suitable statistical measure of rate of change in the plot.
  • the calculated rate of change may or may not be displayed on the plot.
  • S130 includes mathematically calculating the rate of change.
  • the calculation may be similar to the first variation except the computation is performed without graphing the set of average values on a plot.
  • S130 includes determining a trend of multiple biomechanical properties. For example, initial values of multiple biomechanical properties may be characterized relative to each other, such as by plotting (or comparing in any suitable manner, such as by calculating a ratio) the initial value of one biomechanical property against another biomechanical property. For example, in determining a trend of multiple biomechanical properties, the initial value of acoustic speed of the tissue may be compared to the initial value of acoustic attenuation of the tissue.
  • multiple time- dependent representative values e.g., chronological average values
  • those of another biomechanical property such as on a multi-dimensional plot having time-dependent values of acoustic speed on one axis, time-dependent values of acoustic attenuation on another axis, and potentially a temporal variable on a third axis, or on a plot having a ratio of two biomechanical properties on one axis and a temporal variable on another axis.
  • determining a trend of the biomechanical property S132 may include graphing the set of average values of the biomechanical property on a plot against a temporal variable, similar to the plot of the first variation, and characterizing the general shape of the curve formed by the plot.
  • the general shape e.g., a plateau
  • the trend of the biomechanical property shown on the plot may be described as having a certain type of slope or plateau indicating an approximately degree of gradient or flatness, respectively.
  • the step of predicting response of the tissue S140 based on the trend of the biomechanical property functions to characterize the tissue response to the treatment plan.
  • the trend of the biomechanical property may be assessed for change in tissue properties, such as for long-term multiple stage intervention like chemotherapy and radiation therapy, or for cell death as a result of ablation interventions like cryotherapy, radiofrequency (RF) ablation, or electroporation.
  • predicting response of the tissue S140 preferably includes comparing the rate of change to a threshold S142.
  • the threshold may be quantitative, or qualitative.
  • the threshold is preferably based on data characterizing the response of prior patients to the treatment plan, such that prior patients undergoing the treatment plan form a baseline to which current patients may be compared.
  • thresholds may be determined with prior experimental data of patients who were scanned and analyzed according to the preferred method. Some or all of these prior patients may have completed the treatment plan, and additional means such as MRI or PET scans may have been used to determine whether these patients responded or did not respond to the treatment plan, and to what degree of success the responsive patients had with the treatment plan. Analysis of prior patients' experimental data may yield multiple thresholds that indicate varying thresholds of predicted responsiveness (e.g., "complete”, “partial”, or "nonresponsive") to the treatment plan.
  • the threshold may be a "success" threshold, such that if the rate of change (or any singular value, such as an initial baseline value) of the biomechanical property is at and/or above the success threshold, the patient is predicted to respond positively to the continued treatment plan. Furthermore, in this variation, if the rate of change does not meet the success threshold, then the patient is predicted to not respond favorably to the treatment. The exact comparison of the rate of change or other trend relative to the threshold depends on the specific biomechanical property. For example, if the rate of change in acoustic speed in a primary tumor in a particular patient is a declining slope that is steeper than the slope of the success threshold, then the particular patient is predicted to respond positively to the continued treatment plan. However, for other biomechanical properties, the patient may be predicted to respond positively if the rate of change is an inclining slope that is steeper than the slope of the success threshold. Alternatively, the threshold may be considered a "fail" threshold.
  • Predicting response of the tissue S140 may be additionally and/or alternatively include any suitable characteristic of the set of average values of the biomechanical property.
  • predicting response of the tissue S140 includes analyzing the general shape of the curve formed by a plot of the set of average values against a temporal variable.
  • predicting response of the tissue S140 includes analyzing the initial starting value of biomechanical property in the set of average values.
  • predicting response of the tissue S140 includes analyzing the trend of one or more biomechanical property and/or morphological characteristic relative to another biomechanical property and/or morphological characteristic.
  • analyzing the trend may include analyzing the spread or distribution of values on a multi-dimensional plot that has values of one biomechanical property (e.g., acoustic speed) on one axis, values of another biomechanical property (e.g., acoustic attenuation), and potentially a temporal variable on a third axis.
  • analyzing the trend may include analyzing the trend of the ratio between two biomechanical properties (or general shape of the curve formed by a plot of the ratios against a temporal variable).
  • the method may further include modifying the treatment plan based on the predicted response S150, which functions to utilize the predicted response of the tissue to most benefit the patient.
  • the step of modifying the treatment plan based on the predicted response S150 may include maintaining the current treatment plan and/or continuing to monitor the physiological response of the patient.
  • the step of modifying the treatment plan may include: altering characteristics of the treatment plan (such as type of dose, dosage amount, dosage frequency, or distribution pattern of radiation or ablation), administering a different kind of treatment, or aborting the treatment plan.
  • Other suitable modifications dependent on the specific nature and status of the patient as known by one skilled in the art, may be at the physician's discretion.

Abstract

A method of characterizing the pathological response of tissue to a treatment plan, including: obtaining a set of sequential morphology renderings of the tissue, wherein each rendering corresponds to a particular point in time during the treatment plan; generating a set of representative values of a biomechanical property of the tissue for the set of renderings, wherein each representative value is based on a corresponding rendering; determining a trend of the biomechanical property based on the set of representative values; and predicting response of the tissue to the treatment plan based on the trend of the biomechanical property.

Description

METHOD OF CHARACTERIZING THE PATHOLOGICAL RESPONSE OF
TISSUE TO A TREATMENT PLAN
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Patent Application No. 13/027,036 filed 14 FEB 2011 and U.S. Provisional Application No. 61/304,256 filed 12 FEB 2010, which are both incorporated in their entirety by this reference.
TECHNICAL FIELD
[0002] This invention relates generally to the medical field, and more specifically to an improved method of characterizing the pathological response of tissue to a treatment plan in the cancer treatment field.
BACKGROUND
[0003] Common treatments for cancer include removal of cancerous tumor tissue from the patient, radiation treatment, chemotherapy, or ablation interventions, but the most effective treatment or combinations of treatments typically varies from patient to patient. For example, not all cancer patients respond to certain treatments like chemotherapy and radiation treatment, and furthermore not all responsive cancer patients have equal success with these treatments. The success of a treatment for a patient is often not known until the end of the treatment or after a follow-up period after the treatment. However, it is advantageous to be able to accurately predict whether a patient will respond well to a treatment, particularly earlier in the treatment plan, to guide implementation of alternative regimens and/or to abort an unsuccessful treatment plan. Accurate and frequent evaluation of a tumor's response to treatment allows a physician to optimize the treatment plan for the patient, and potentially spare an unresponsive patient from unnecessary side effects from the treatment, such as the physical and emotional toll of chemotherapy-induced side effects. Monitoring the state of tumor tissue in a patient could theoretically be performed with repeated use of magnetic resonance imaging (MRI) or positron emission tomography (PET). However, these technologies are costly and may not be accessible in a community for repeated use, making them ill-suited for frequent evaluation of tumor tissue. Other technologies, such as X-rays, utilize ionizing radiation that precludes frequent use. Thus, there is a need in the medical field to create an improved method of characterizing the pathological response of tissue to a treatment plan. This invention provides such an improved method.
BRIEF DESCRIPTION OF THE FIGURES
[0004] FIGURE l is a schematic of the method of a preferred embodiment;
[0005] FIGURE 2 is a schematic of a scanner that may be used during the step of obtaining a set of sequential morphological renderings of tissue in the method of a preferred embodiment;
[0006] FIGURES 3A-3D are schematics of steps of obtaining a set of sequential morphological renderings of tissue in the method of a preferred embodiment; [0007] FIGURE 4 is a schematic of the step of generating a set of representative values in the method of a preferred embodiment;
[0008] FIGURES 5 and 6 are schematics of variations of determining a trend of the biomechanical property based on a set of representative values of a biomechanical property in the method of a preferred embodiment; and
[0009] FIGURE 7 is a schematic of one variation of predicting response of tissue to a treatment plan based on the trend of a biomechanical property in the method of a preferred embodiment.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The following description of preferred embodiments of the invention is not intended to limit the invention to these preferred embodiments, but rather to enable any person skilled in the art to make and use this invention.
[0011] As shown in FIGURE 1, the method 100 of characterizing the pathological response of tissue to a treatment plan of a preferred embodiment includes the steps of: obtaining a set of sequential morphology renderings of the tissue S110, wherein each rendering corresponds to a particular point in time during the treatment plan; generating a set of representative values of a biomechanical property of the tissue for the set of renderings S120, wherein each representative value is based on a corresponding rendering; determining a trend of the biomechanical property S130 based on the set of representative values; and predicting response of the tissue to the treatment plan S140 based on the trend of the biomechanical property. The method 100 is preferably used to predict and/or monitor the pathological response of cancer, such as breast cancer, to chemotherapy or radiation therapy (or side effects of the therapy), but may additionally and/or alternatively be used to predict or monitor the response of any cancer or benign tumors to any suitable treatment. The method 100 may additionally and/or alternatively be used to predict success of chemoprevention (a pharmacological approach to reducing cancer risk). Predicting and characterizing how a cancer patient will respond to a particular cancer treatment allows a physician to distinguish patients who are likely to have success with the treatment from those patients who are less likely to have success with the treatment, thereby allowing the physician to guide implementation of alternative regimens and/or to abort the particular treatment. Such knowledge about patient response to the treatment enables the physician to, for example, spare an unresponsive patient from suffering side effects of chemotherapy or radiation therapy and from applying potentially limited financial means towards an ineffective treatment, and move towards optimizing the efficacy of a treatment plan. The trend, such as rate of change, of the biomechanical property of the tumor early in the treatment plan is preferably used to predict the full treatment response, but the trend of the biomechanical property at any stage in the treatment plan may additionally and/or alternatively be used. The method 100 may facilitate an accurate and frequent evaluation of the tumor response to other therapies, such as to evaluate the clinical efficacy of a new therapeutic agent or regimen.
[0012] The step of obtaining a set of sequential morphology renderings Sno functions to obtain data from the patient. This data forms the basis of analysis in characterizing the response of the tissue to a cancer treatment. The morphology renderings preferably include renderings of tumor tissue, and may additionally and/or alternatively include renderings of healthy tissue such as that surrounding the tumor tissue. The morphology renderings may additionally and/or alternatively broken bones or any suitable tissue. Each rendering preferably corresponds to a particular point in time during the treatment plan, such that the set of renderings represent sequential, chronological snapshots of the tissue at various points in time during the treatment plan. For example, obtaining a rendering may be performed hourly, daily, every few days, every 1-3 weeks, or any suitable frequency, or performed in correspondence (e.g., immediately before and/or immediately after) a treatment phase such as a chemotherapy treatment. Obtaining a set of renderings S110 is preferably performed in early stages of a treatment plan (e.g., within the first several months), but may alternatively be performed during any suitable portion of the treatment plan. The set of renderings may be taken at approximately regular time intervals during the treatment plan, or at irregular time intervals (for example, the timing of the renderings may depend on particular scheduling of chemotherapy treatments). In a preferred embodiment, obtaining a set of renderings S110 preferably includes scanning the tissue with an ultrasound scanner to obtain acoustic data S112 and creating images representing acoustic parameters of the tissue with the acoustic data S114. The steps of scanning the tissue and creating images are each preferably performed at least once each time a single rendering is obtained, such that the steps of scanning the tissue and creating images are repeated multiple times. Obtaining a set of renderings S110 may additionally and/or alternatively include retrieving a set of images or renderings from a storage device such as a hard drive or an online server, or any suitable storage such as hard copy patient records.
[0013] The step of scanning the tissue S112 preferably includes surrounding the tissue with a transducer that transmits and receives acoustic waves through the tissue. For example, as shown in FIGURES 2 and 3A, to scan breast tissue of a breast cancer patient with an ultrasound tomography scanner having a ring-shaped transducer, the patient positions themselves face down on a flexible bed having a hole in the chest region of the bed. The breast of the patient passes through the hole in the bed and is positioned within the transducer immersed in a water bath. The ring transducer is preferably fixed to a gantry, and, during the scanning step S112, moves in a vertical path to pass between the chest wall and the nipple region in an anterior-posterior direction, thereby preferably imaging the entire breast (alternatively a selected portion of the breast). The scanner is preferably similar to that described in U.S. Patent Publication No. 2008/0275344 entitled "Method and apparatus for categorizing breast density and assessing cancer risk utilizing acoustic parameters", which is incorporated in its entirety by this reference. However, the ring transducer may be used to scan any suitable tissue, such as an arm, hand, leg, or foot. The scanner is preferably relatively inexpensive, quick, and more comfortable for the patient and easy to install and operate. The scanning step preferably gathers acoustic data including acoustic reflection from tissue, acoustic attenuation within tissue, and/or acoustic speed within tissue. However, the scanning step may additionally and/or alternatively gather any other acoustic data or suitable biomechanical property of the tissue. The method may alternatively include obtaining a set of morphology renderings using magnetic resonance imaging (MRI), positron emission tomography (PET), or any suitable device to generate renderings of tissue. For example, PET may be used to assess metabolic changes in tissue to generate tissue images.
[0014] The step of creating images representing acoustic parameters of the tissue S114 preferably includes generating one or more two-dimensional (2D) images from the acoustic data obtained during the scanning step, and may include generating one or more three-dimensional (3D) images of the tissue. In a preferred embodiment, as shown in FIGURE 3C, generating one or more 2D images includes generating a plurality of 2D cross-sectional images (e.g., "slices" in the coronal plane, or any suitable plane) of the tissue S116 and combining the 2D cross-sectional images of the tissue into a 3D image of the tissue S118. The images are preferably tomography images, and more preferably ultrasound tomography images, although they may alternatively be any suitable tomography imges. A general process for combining stacks of 2D images into a 3D image is known by one skilled in the art, but one possible process is described in U.S. Patent Publication No. 2008/0275344. Alternatively, the 2D and/or 3D images may be generated in any suitable manner. As shown in FIGURE 3D, in the step of obtaining a set of sequential morphology renderings S110, the steps of scanning and creating images are preferably repeated until a chronological set of renderings of the tissue (preferably 3D) are obtained, such that the set includes a morphological rendering at times ti, t2, t3... tn are obtained. The images preferably represent at least one of acoustic reflection from the tissue, acoustic attenuation within the tissue, and acoustic speed within the tissue. However, the images may additionally and/or alternatively represent any suitable biomechanical property of the tissue. For example, the images may represent the tissue under Doppler radar or the interaction of the tissue with a contrast agent (e.g., uptake or kinetics of flow). As shown in FIGURE 3B, each acoustic parameter is preferably imaged in a separate stack of 2D images, such that at each cross-sectional level in the stack, the images for acoustic reflection (Ir), attenuation (la), and/or acoustic speed (Is) can be overlaid or combined into a merged 2D image.
[0015] The step of generating a set of representative values of a biomechanical property S120 functions to quantify or otherwise characterize the biomechanical property in the set of renderings. As shown in FIGURE 4, the step of generating a set of representative values S120 preferably includes calculating an average value of the biomechanical property for each rendering S122, thereby generating a set of sequential or chronological volume average values of the biomechanical property of the tissue. Generating a set of representative values S120 may further include normalizing the set of representative values, such as to remove statistical error from the measured data. The generated representative values of the set of renderings are preferably of acoustic speed, but may additionally and/or include acoustic attenuation, acoustic speed, tissue density, and/or any suitable biomechanical property. In a preferred embodiment, the average value is a volume average of the biomechanical property in a primary tumor in the patient. The primary tumor is preferably defined by locating an outline of the tumor mass as it appears on the morphology renderings of the acoustic reflection image, and the tumor outline may be replicated on the acoustic attenuation and/or acoustic speed morphology renderings to show the boundary of the primary tumor. The volume average preferably incorporates the mean value of the biomechanical property within the volume of the primary tumor as characterized by the renderings. For example, an average volumetric acoustic speed may be calculated as described in U.S. Patent Publication No. 2008/0275344. However, the volume average may be a representative value of the biomechanical property in the primary tumor calculated in any suitable manner. For example, the volume average may additionally and/or alternatively include other aspects, such as being weighted by a spatial distribution of the values of the biomechanical property throughout the primary tumor. In another example, the volume average may take into account a combination of multiple different kinds of biomechanical properties throughout the primary tumor.
[0016] In one variation, the average value may be the mean or other statistical average of multiple volume averages of the multiple tumors, or the maximum volume average value of the multiple volume averages of multiple tumors. In another variation, the average value is the mean or other statistical average of any suitable healthy or unhealthy portion of the rendered tissue. However, the average value may alternatively be any suitable average value.
[0017] Calculating an average value of the biomechanical property for each rendering S122 preferably includes accounting for the difference between the value of the biomechanical property within the tumor tissue and the value of the biomechanical property in background tissue surrounding the tumor tissue S124. Accounting for the difference functions to disregard the value of the biomechanical property in the background tissue. Preferably, accounting for the difference S124 includes subtracting an average value of the biomechanical property in background tissue from the volume average value of the biomechanical property of the tumor tissue S126, but the difference may be accounted for in any suitable manner. The boundary of background tissue relative to tumor tissue in each rendering may be defined in one or more of several manners. In one variation, the background tissue may be defined as a region beyond a distance threshold (e.g., 2 centimeters) beyond the boundary of the outlined tumor tissue. In another variation, the background tissue may be defined as a region beyond a boundary where the gradient in the biomechanical property satisfies a difference threshold. However, the boundary of background tissue relative to tumor tissue may be defined in any suitable manner.
[0018] In another variation, generating a set of representative values S120 includes determining an initial or baseline value of the biomechanical property, or any suitable singular value of the biomechanical property. For instance, the initial value may be taken from the first rendering obtained in step S110. Furthermore, determining a trend of the biomechanical property S130 may include characterizing initial values of multiple biomechanical properties, or any suitable singular values of multiple biomechanical properties.
[0019] Alternatively, generating a set of representative values S120 may include characterizing the spatial distribution of the biomechanical property in each of the set of renderings. The characterization may be qualitative, or may be quantitative such as by generating a parameter descriptive of the spatial distribution of the biomechanical property. Generating a set of representative values S120 may include characterizing the spatial distribution of acoustic speed in an acoustic rendering, but may additionally and/or alternatively include characterizing the spatial distribution of acoustic attenuation or any suitable biomechanical property.
[0020] The step of determining a trend of the biomechanical property S130 functions to generate metrics, based on the acoustic data, that may be analyzed for predicting or otherwise characterizing patient response to a treatment plan. Determining a trend S130 preferably includes calculating a rate of change in the set of average values S132, which may be one or more of several variations. In a first variation, as shown in FIGURE 6, determining a trend of the biomechanical property S130 includes graphing the set of average values of the biomechanical property on a plot against a temporal variable (e.g., number of days of treatment or number of treatments) S134. Each value of the set of average values may be expressed as an absolute value, expressed as a percentage of the first average value of the set, or in any suitable manner. In this variation, calculating a rate of change S132 preferably includes calculating a slope of a best-fit curve fitted to at least a portion of the plot. In other words, the calculated rate of change in the biomechanical property may be the slope of a best-fit curve fitted to two or more values in the set of volume average values. Alternatively, the calculated rate of change may be the slope between the first and last average values, the mean or median of slopes between subsets of adjacent pairs of average values, percentage difference between two or more points on the plots, or any suitable statistical measure of rate of change in the plot. The calculated rate of change may or may not be displayed on the plot.
[0021] In a second variation, determining a trend of the biomechanical property
S130 includes mathematically calculating the rate of change. The calculation may be similar to the first variation except the computation is performed without graphing the set of average values on a plot.
[0022] In a third variation, determining a trend of the biomechanical property
S130 includes determining a trend of multiple biomechanical properties. For example, initial values of multiple biomechanical properties may be characterized relative to each other, such as by plotting (or comparing in any suitable manner, such as by calculating a ratio) the initial value of one biomechanical property against another biomechanical property. For example, in determining a trend of multiple biomechanical properties, the initial value of acoustic speed of the tissue may be compared to the initial value of acoustic attenuation of the tissue. Furthermore, as shown in FIGURE 6, multiple time- dependent representative values (e.g., chronological average values) of one biomechanical property may be compared to those of another biomechanical property, such as on a multi-dimensional plot having time-dependent values of acoustic speed on one axis, time-dependent values of acoustic attenuation on another axis, and potentially a temporal variable on a third axis, or on a plot having a ratio of two biomechanical properties on one axis and a temporal variable on another axis.
[0023] In an alternative embodiment, determining a trend of the biomechanical property S132 may include graphing the set of average values of the biomechanical property on a plot against a temporal variable, similar to the plot of the first variation, and characterizing the general shape of the curve formed by the plot. The general shape (e.g., a plateau) of the curve may be characterized quantitatively and/or qualitatively. For example, the trend of the biomechanical property shown on the plot may be described as having a certain type of slope or plateau indicating an approximately degree of gradient or flatness, respectively.
[0024] The step of predicting response of the tissue S140 based on the trend of the biomechanical property functions to characterize the tissue response to the treatment plan. During the predicting step, the trend of the biomechanical property may be assessed for change in tissue properties, such as for long-term multiple stage intervention like chemotherapy and radiation therapy, or for cell death as a result of ablation interventions like cryotherapy, radiofrequency (RF) ablation, or electroporation. As shown in FIGURE 7, predicting response of the tissue S140 preferably includes comparing the rate of change to a threshold S142. The threshold may be quantitative, or qualitative. The threshold is preferably based on data characterizing the response of prior patients to the treatment plan, such that prior patients undergoing the treatment plan form a baseline to which current patients may be compared. For example, thresholds may be determined with prior experimental data of patients who were scanned and analyzed according to the preferred method. Some or all of these prior patients may have completed the treatment plan, and additional means such as MRI or PET scans may have been used to determine whether these patients responded or did not respond to the treatment plan, and to what degree of success the responsive patients had with the treatment plan. Analysis of prior patients' experimental data may yield multiple thresholds that indicate varying thresholds of predicted responsiveness (e.g., "complete", "partial", or "nonresponsive") to the treatment plan.
[0025] In a preferred variation, the threshold may be a "success" threshold, such that if the rate of change (or any singular value, such as an initial baseline value) of the biomechanical property is at and/or above the success threshold, the patient is predicted to respond positively to the continued treatment plan. Furthermore, in this variation, if the rate of change does not meet the success threshold, then the patient is predicted to not respond favorably to the treatment. The exact comparison of the rate of change or other trend relative to the threshold depends on the specific biomechanical property. For example, if the rate of change in acoustic speed in a primary tumor in a particular patient is a declining slope that is steeper than the slope of the success threshold, then the particular patient is predicted to respond positively to the continued treatment plan. However, for other biomechanical properties, the patient may be predicted to respond positively if the rate of change is an inclining slope that is steeper than the slope of the success threshold. Alternatively, the threshold may be considered a "fail" threshold.
[0026] Predicting response of the tissue S140 may be additionally and/or alternatively include any suitable characteristic of the set of average values of the biomechanical property. For example, in one alternative variation, predicting response of the tissue S140 includes analyzing the general shape of the curve formed by a plot of the set of average values against a temporal variable. In another variation, predicting response of the tissue S140 includes analyzing the initial starting value of biomechanical property in the set of average values. In yet another variation, predicting response of the tissue S140 includes analyzing the trend of one or more biomechanical property and/or morphological characteristic relative to another biomechanical property and/or morphological characteristic. For example, analyzing the trend may include analyzing the spread or distribution of values on a multi-dimensional plot that has values of one biomechanical property (e.g., acoustic speed) on one axis, values of another biomechanical property (e.g., acoustic attenuation), and potentially a temporal variable on a third axis. In another example, analyzing the trend may include analyzing the trend of the ratio between two biomechanical properties (or general shape of the curve formed by a plot of the ratios against a temporal variable).
[0027] The method may further include modifying the treatment plan based on the predicted response S150, which functions to utilize the predicted response of the tissue to most benefit the patient. For example, if the prediction is that the patient will respond favorably to the treatment plan, then the step of modifying the treatment plan based on the predicted response S150 may include maintaining the current treatment plan and/or continuing to monitor the physiological response of the patient. As another example, if the prediction is that the patient will not respond favorably to the treatment, then the step of modifying the treatment plan may include: altering characteristics of the treatment plan (such as type of dose, dosage amount, dosage frequency, or distribution pattern of radiation or ablation), administering a different kind of treatment, or aborting the treatment plan. Other suitable modifications, dependent on the specific nature and status of the patient as known by one skilled in the art, may be at the physician's discretion.
[0028] As a person skilled in the art will recognize from the previous detailed description and from the figures and claims, modifications and changes can be made to the preferred embodiments of the invention without departing from the scope of this invention defined in the following claims.

Claims

CLAIMS We Claim:
1. A method of characterizing the pathological response of tissue to a treatment plan, comprising:
• obtaining a set of sequential morphology renderings of the tissue, wherein each rendering corresponds to a particular point in time during the treatment plan;
• generating a set of representative values of a biomechanical property of the tissue for the set of renderings, wherein each representative value is based on a corresponding rendering;
• determining a trend of the biomechanical property based on the set of representative values; and
• predicting response of the tissue to the treatment plan based on the trend of the biomechanical property.
2. The method of Claim l, wherein obtaining a set of sequential morphology renderings includes obtaining a set of morphology renderings of tumor tissue.
3. The method of Claim 1, wherein obtaining a set of sequential morphology renderings includes scanning the tissue to obtain acoustic data and creating images representing acoustic parameters of the tissue with the acoustic data.
4. The method of Claim 3, wherein scanning the tissue includes scanning with an ultrasound scanner.
5. The method of Claim 3, wherein creating images includes creating images representing at least one of acoustic reflection from the tissue, acoustic attenuation within the tissue, and acoustic speed within the tissue.
6. The method of Claim 4, wherein creating images includes generating one or more two-dimensional images.
7. The method of Claim 6, wherein creating images includes generating a plurality of two-dimensional cross-sectional images of the tissue and combining the cross- sectional images into a three-dimensional image of the tissue.
8. The method of Claim 7, wherein scanning the tissue includes surrounding breast tissue with a ring transducer and passing the ring transducer along an anterior-posterior direction relative to the breast tissue.
9. The method of Claim 3, wherein scanning the tissue and creating images are repeated at regular time intervals during the treatment plan.
10. The method of Claim 1, wherein generating a set of representative values of a biomechanical property includes calculating a volume average value of the biomechanical property of the tissue for each rendering, thereby generating a sequential set of volume average values of the biomechanical property of the tissue.
11. The method of Claim 10, wherein calculating a volume average value includes calculating a volume average value of acoustic speed within the tissue for each rendering.
12. The method of Claim 10, wherein calculating a volume average value includes calculating a volume average value of breast density within the tissue for each rendering.
13. The method of Claim 10, wherein calculating a volume average value includes calculating a volume average value of the biomechanical property of tumor tissue, thereby generating a set of volume average values of the biomechanical property of tumor tissue.
14. The method of Claim 13, wherein calculating the volume average value of the biomechanical property of the tumor tissue includes accounting for the difference between the value of the biomechanical property within the tumor tissue and the value of the biomechanical property in background tissue surrounding the tumor tissue.
15. The method of Claim 14, wherein accounting for the difference includes subtracting an average value of the biomechanical property in background tissue from the volume average value of the biomechanical property of the tumor tissue.
16. The method of Claim 14, wherein calculating the volume average value of the biomechanical property of the tumor tissue includes calculating the volume average value of acoustic speed within the tumor tissue.
17. The method of Claim 1, wherein generating a set of representative values includes determining an initial or baseline value of the biomechanical property.
18. The method of Claim 1, wherein generating a set of representative values includes characterizing the spatial distribution of the biomechanical property in each of the set of renderings.
19. The method of Claim 1, wherein determining a trend of the biomechanical property in the tissue includes calculating a rate of change in the set of representative values.
20. The method of Claim 19, wherein calculating a rate of change includes calculating a slope of a best-fit curve fitted to two or more values in the set of representative values.
21. The method of Claim 19, wherein predicting response of the tissue includes comparing the rate of change to a threshold.
22. The method of Claim 21, wherein comparing the rate of change to a threshold includes comparing the rate of change to a threshold that is based on data characterizing response of prior patients to the treatment plan.
23. The method of Claim 1, wherein determining a trend of the biomechanical property in the tissue includes analyzing the general shape of the curve formed by a plot of the set of average values against a temporal variable.
24. The method of Claim 1, wherein predicting response of the tissue includes comparing the trend of the biomechanical property to a threshold.
25. The method of Claim 1, wherein predicting response of the tissue includes analyzing the trend of one or more biomechanical property relative to another biomechanical property.
26. The method of Claim 1, wherein determining a trend includes determining a trend of acoustic speed within the tissue in the sequential morphology renderings.
27. The method of Claim 1, wherein determining a trend includes determining a trend in volume average value of acoustic attenuation within the tissue in the sequential morphology renderings.
28. The method of Claim 1, wherein determining a trend includes determining a trend in acoustic reflection within the tissue in the sequential morphology renderings.
29. The method of Claim 1, wherein determining a trend includes determining a trend in Doppler measurements in the sequential morphology renderings.
30. The method of Claim 1, wherein determining a trend includes determining a trend in contrast agent uptake measurements in the sequential morphology renderings.
31. The method of Claim 1, further comprising modifying the treatment plan based on the predicted response.
32. A method of characterizing pathological response of a tumor in patient tissue to a treatment plan, comprising:
• obtaining a set of sequential ultrasound morphology renderings of the tissue, wherein each rendering corresponds to a different point in time during the treatment plan; • generating a set of volume average values of acoustic speed within the tumor for the set of renderings, wherein each volume average value is based on a corresponding rendering;
• calculating a rate of change in acoustic speed within the tumor based on the set of volume average values; and
• predicting response of the tumor to the treatment plan based on the rate of change of the sound speed within the tumor.
33. The method of Claim 32, wherein obtaining a set of sequential ultrasound morphology renderings includes generating a plurality of two-dimensional cross- sectional images of the tumor and combining the cross-sectional images into a three- dimensional image of the tumor.
34. The method of Claim 33, wherein obtaining a set of sequential ultrasound morphology renderings includes scanning the tumor tissue with a ring transducer and passing the ring transducer along an anterior-posterior direction relative to the tumor tissue.
35. The method of Claim 32, wherein calculating a rate of change in acoustic speed within the tumor includes calculating a slope of a best-fit curve fitted to two or more values in the set of volume average values.
36. The method of Claim 32, wherein predicting response of the tumor includes comparing the rate of change to a threshold that is based on data characterizing response of prior patients to the treatment plan.
37. The method of Claim 32, further comprising modifying the treatment plan based on the predicted response.
EP11742965.4A 2010-02-12 2011-02-14 Method of characterizing the pathological response of tissue to a treatmant plan Withdrawn EP2533683A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30425610P 2010-02-12 2010-02-12
PCT/US2011/024765 WO2011100691A1 (en) 2010-02-12 2011-02-14 Method of characterizing the pathological response of tissue to a treatmant plan

Publications (2)

Publication Number Publication Date
EP2533683A1 true EP2533683A1 (en) 2012-12-19
EP2533683A4 EP2533683A4 (en) 2013-07-31

Family

ID=47143443

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11742965.4A Withdrawn EP2533683A4 (en) 2010-02-12 2011-02-14 Method of characterizing the pathological response of tissue to a treatmant plan

Country Status (1)

Country Link
EP (1) EP2533683A4 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060064014A1 (en) * 2004-09-20 2006-03-23 Tony Falco Radiotherapy treatment monitoring using ultrasound
US20080281205A1 (en) * 2004-01-16 2008-11-13 Morteza Naghavi Methods and Apparatuses For Medical Imaging
US20080294027A1 (en) * 2003-06-12 2008-11-27 Bracco Research Sa System for extracting morphological information through a perfusion assessment process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080294027A1 (en) * 2003-06-12 2008-11-27 Bracco Research Sa System for extracting morphological information through a perfusion assessment process
US20080281205A1 (en) * 2004-01-16 2008-11-13 Morteza Naghavi Methods and Apparatuses For Medical Imaging
US20060064014A1 (en) * 2004-09-20 2006-03-23 Tony Falco Radiotherapy treatment monitoring using ultrasound

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B. BANIHASHEMI ET AL: "Ultrasound Imaging of Apoptosis in Tumor Response: Novel Preclinical Monitoring of Photodynamic Therapy Effects", CANCER RESEARCH, vol. 68, no. 20, 15 October 2008 (2008-10-15), pages 8590-8596, XP55066759, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-0006 *
LI C ET AL: "In vivo Breast Sound-Speed Imaging with Ultrasound Tomography", ULTRASOUND IN MEDICINE AND BIOLOGY, NEW YORK, NY, US, vol. 35, no. 10, 1 October 2009 (2009-10-01), pages 1615-1628, XP026641057, ISSN: 0301-5629, DOI: 10.1016/J.ULTRASMEDBIO.2009.05.011 [retrieved on 2009-08-03] *
See also references of WO2011100691A1 *
SINGH SEEMA ET AL: "Color Doppler ultrasound as an objective assessment tool for chemotherapeutic response in advanced breast cancer.", BREAST CANCER (TOKYO, JAPAN) 2005, vol. 12, no. 1, 2005, pages 45-51, XP002698852, ISSN: 1340-6868 *
YAMAN C ET AL: "Three-dimensional ultrasound to assess the response to treatment in gynecological malignancies", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 97, no. 2, 1 May 2005 (2005-05-01), pages 665-668, XP004879600, ISSN: 0090-8258, DOI: 10.1016/J.YGYNO.2005.01.012 *

Also Published As

Publication number Publication date
EP2533683A4 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US20200015775A1 (en) Method of characterizing the pathological response of tissue to a treatment plan
US20230089236A1 (en) Method of characterizing tissue of a patient
EP3806721B1 (en) Method and system for determining fractional fat content of tissue
RU2633322C2 (en) System and method of hybrid surface radiotherapy with ultrasound control
Duric et al. Breast density measurements with ultrasound tomography: A comparison with film and digital mammography
KR101900122B1 (en) Ultrasound apparatus for assessing the quality of a patient’s bone tissue
CN107569256B (en) Ultrasonic method for measuring temperature change of biological tissue based on thermal expansion and gating algorithm
US20200253580A1 (en) Tissue lesion detection and determination using quantitative transmission ultrasound
EP2533683A1 (en) Method of characterizing the pathological response of tissue to a treatmant plan
WO2021048776A1 (en) Method for evaluating the presence of sarcopenia by magnetic resonance or echography or computed tomography
Xiao et al. Simple ways to estimate meningioma volume: can abc-and sh-derived methods be used in clinical practice reliably?
JP7182318B2 (en) Systems and methods for identifying fluid retention in body parts
EP2533684A1 (en) Method of characterizing tissue of a patient
RU2449724C1 (en) Method of estimating efficiency of diffuse mastopatia treatment
Qin et al. Comparison of reproducibility of manual and sphere contour methods for the measurement of vascularization in cervical carcinoma using the virtual organ computer‐aided analysis II system
Rodriguez et al. Skeletal muscle estimation: A review of techniques and their applications
Lupinacci et al. Monitoring breast masses with ultrasound tomography in patients undergoing neoadjuvant chemotherapy
Lupinacci et al. Monitoring breast masses with ultrasound tomography in patients undergoing neoadjuvant chemotherapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120807

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/00 20060101AFI20130620BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130627

17Q First examination report despatched

Effective date: 20140710

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141121